# LY6G6D

## Overview
LY6G6D is a gene located in the major histocompatibility complex (MHC) class III region on chromosome 6p21.3, encoding the protein lymphocyte antigen 6 family member G6D. This protein is a member of the Ly6/uPAR family, characterized by a conserved LU domain with a three-fingered protein fold, and is anchored to the cell surface via a glycosylphosphatidylinositol (GPI) anchor, typical of membrane-tethered proteins in this family (Loughner2016Organization; Giordano2019JAKStat5mediated). LY6G6D is involved in immune-related functions and is expressed in various tissues, including the colon, testicular, and prostate tissues (Caruso2022Lymphocyte). The gene's expression and regulation are complex, involving processes such as intron retention and transcription-induced chimerism, which suggest roles in gene regulation and immune modulation (Calvanese2008Regulation). In the context of disease, LY6G6D is notably implicated in colorectal cancer, where it is associated with an immunosuppressive microenvironment and potential resistance to chemotherapy, making it a target for therapeutic strategies (Sanvicente2024Clinical; Caruso2021LY6G6D).

## Structure
LY6G6D is a protein that belongs to the Ly6/uPAR family, characterized by a conserved LU domain with a three-fingered protein fold, similar to snake venom neurotoxins. This domain is stabilized by disulfide bridges connecting conserved cysteine residues, forming a core from which three β-sheet loops protrude (Loughner2016Organization). The protein is composed of 133 amino acids and is anchored to the cell surface via a glycosylphosphatidylinositol (GPI) anchor, which is typical for membrane-tethered members of this family (Loughner2016Organization; Giordano2019JAKStat5mediated).

The primary structure of LY6G6D includes a signal peptide encoded by the first exon, while the mature polypeptide is encoded by the last two exons (Loughner2016Organization). The protein may undergo post-translational modifications such as glycosylation and disulfide bond formation, contributing to its functional diversity. LY6G6D also has splice variant isoforms, which may result in different functional roles (Calvanese2008Regulation).

The protein's tertiary structure was modeled using computational tools, with the Robetta server generating five predicted structures. Model 01 was selected as the most reliable based on validation scores and was further refined using the Galaxy server (Mehwish2024Decoding). The structure includes conserved regions that may be important for interactions, as identified through evolutionary conservation analysis (Mehwish2024Decoding).

## Function
LY6G6D is a member of the LY-6 superfamily, which is involved in immune-related roles. It is located in the MHC class III region on chromosome 6p21.3 and encodes LY-6 domain proteins (Calvanese2008Regulation). In healthy human cells, LY6G6D is expressed in fibroblasts and is associated with filopodia functions, which are involved in cell movement and signaling (Loughner2016Organization). The protein is expressed in various tissues, with moderate expression in the normal colon, particularly the sigmoid colon, and strong expression in testicular and prostate tissues (Caruso2022Lymphocyte).

The regulation of LY6G6D involves complex molecular processes, including intron retention and transcription-induced chimerism. Intron retention results in non-coding transcripts due to a premature stop codon, suggesting a regulatory function beyond traditional protein-coding roles (Calvanese2008Regulation). The gene can also form chimeric transcripts with neighboring genes, such as G6F, through transcription-induced chimerism, which may contribute to proteome complexity and gene regulation (Calvanese2008Regulation). These processes indicate that LY6G6D may play roles in gene regulation or immune system modulation, although its specific functions in healthy cells remain to be fully elucidated.

## Clinical Significance
The LY6G6D gene is implicated in colorectal cancer (CRC), where its expression is notably elevated in tumor tissues compared to normal tissues. This gene is particularly associated with microsatellite stable (MSS) subtypes of CRC, where it is linked to an immunosuppressive microenvironment characterized by reduced infiltration of immune cells such as CD8+ T cells, CD4+ T cells, and neutrophils (Sanvicente2024Clinical; Giordano2019JAKStat5mediated). High LY6G6D expression is also correlated with mutations in genes like APC and TP53, while showing a negative association with KRAS mutations (Sanvicente2024Clinical).

In classical colorectal adenocarcinoma, LY6G6D is epigenetically activated, whereas in mucinous subtypes, it is hyper-methylated, leading to resistance to FOLFOX chemotherapy regimens (Caruso2021LY6G6D). The gene's expression is regulated by pathways such as JAK/STAT5, which are involved in immune resistance mechanisms, suggesting that LY6G6D may contribute to immune evasion in CRC (Giordano2019JAKStat5mediated).

LY6G6D's role as a tumor-associated antigen (TAA) makes it a potential target for therapeutic strategies, including T cell engagers, aimed at selectively targeting CRC cells while minimizing off-target effects (Sanvicente2024Clinical).

## Interactions



## References


[1. (Caruso2022Lymphocyte) Francesca Pia Caruso, Mario Rosario D’Andrea, Luigi Coppola, Matteo Landriscina, Valentina Condelli, Luigi Cerulo, Guido Giordano, Almudena Porras, and Massimo Pancione. Lymphocyte antigen 6g6d-mediated modulation through p38α mapk and dna methylation in colorectal cancer. Cancer Cell International, August 2022. URL: http://dx.doi.org/10.1186/s12935-022-02672-1, doi:10.1186/s12935-022-02672-1. This article has 4 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s12935-022-02672-1)

[2. (Sanvicente2024Clinical) Adrián Sanvicente García, Manuel Pedregal, Lucía Paniagua-Herranz, Cristina Díaz-Tejeiro, Cristina Nieto-Jiménez, Pedro Pérez Segura, Gyöngyi Munkácsy, Balázs Győrffy, Emiliano Calvo, Víctor Moreno, and Alberto Ocaña. Clinical and immunologic characteristics of colorectal cancer tumors expressing ly6g6d. International Journal of Molecular Sciences, 25(10):5345, May 2024. URL: http://dx.doi.org/10.3390/ijms25105345, doi:10.3390/ijms25105345. This article has 0 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/ijms25105345)

[3. (Loughner2016Organization) Chelsea L. Loughner, Elspeth A. Bruford, Monica S. McAndrews, Emili E. Delp, Sudha Swamynathan, and Shivalingappa K. Swamynathan. Organization, evolution and functions of the human and mouse ly6/upar family genes. Human Genomics, April 2016. URL: http://dx.doi.org/10.1186/s40246-016-0074-2, doi:10.1186/s40246-016-0074-2. This article has 158 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s40246-016-0074-2)

[4. (Giordano2019JAKStat5mediated) Guido Giordano, Pietro Parcesepe, Mario Rosario D’Andrea, Luigi Coppola, Tania Di Raimo, Andrea Remo, Erminia Manfrin, Claudia Fiorini, Aldo Scarpa, Carla Azzurra Amoreo, Fabiana Conciatori, Michele Milella, Francesca Pia Caruso, Luigi Cerulo, Almudena Porras, and Massimo Pancione. Jak/stat5-mediated subtype-specific lymphocyte antigen 6 complex, locus g6d (ly6g6d) expression drives mismatch repair proficient colorectal cancer. Journal of Experimental &amp; Clinical Cancer Research, January 2019. URL: http://dx.doi.org/10.1186/s13046-018-1019-5, doi:10.1186/s13046-018-1019-5. This article has 23 citations.](https://doi.org/10.1186/s13046-018-1019-5)

5. (Caruso2021LY6G6D) LY6G6D is Epigenetically Activated in Classical Colorectal Adenocarcinoma and Hyper-Methylated in Mucinous Subtypes Determining Resistance to FOLFOX Therapeutic Regimens. This article has 0 citations.

[6. (Calvanese2008Regulation) Vincenzo Calvanese, Meera Mallya, R Duncan Campbell, and Begoña Aguado. Regulation of expression of two ly-6 family genes by intron retention and transcription induced chimerism. BMC Molecular Biology, 9(1):81, 2008. URL: http://dx.doi.org/10.1186/1471-2199-9-81, doi:10.1186/1471-2199-9-81. This article has 8 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/1471-2199-9-81)

[7. (Mehwish2024Decoding) Mehwish Naqvi, Waqas Ahmad Abbasi, Muhammad Kaleem Samma, Asif Ali Gabol, Cynthia Innocent, Sana Iqbal, Samana Fatima, and Kashif Ali. Decoding ly6g6d in colorectal cancer: unraveling biomarker potential and therapeutic insights. Cellular and Molecular Biology, 70(6):14–20, June 2024. URL: http://dx.doi.org/10.14715/cmb/2024.70.6.3, doi:10.14715/cmb/2024.70.6.3. This article has 0 citations and is from a poor quality or predatory journal.](https://doi.org/10.14715/cmb/2024.70.6.3)